PRME
Price
$2.89
Change
+$0.02 (+0.70%)
Updated
Jan 17 closing price
Capitalization
379.05M
47 days until earnings call
SLDB
Price
$3.27
Change
+$0.02 (+0.62%)
Updated
Jan 17 closing price
Capitalization
130.65M
Ad is loading...

PRME vs SLDB

Header iconPRME vs SLDB Comparison
Open Charts PRME vs SLDBBanner chart's image
Prime Medicine
Price$2.89
Change+$0.02 (+0.70%)
Volume$480.24K
Capitalization379.05M
Solid Biosciences
Price$3.27
Change+$0.02 (+0.62%)
Volume$495.11K
Capitalization130.65M
PRME vs SLDB Comparison Chart
Loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRME vs. SLDB commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Hold and SLDB is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (PRME: $2.89 vs. SLDB: $3.27)
Brand notoriety: PRME and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 42% vs. SLDB: 115%
Market capitalization -- PRME: $379.05M vs. SLDB: $130.65M
PRME [@Biotechnology] is valued at $379.05M. SLDB’s [@Biotechnology] market capitalization is $130.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileSLDB’s FA Score has 2 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 4 TA indicator(s) are bullish while SLDB’s TA Score has 4 bullish TA indicator(s).

  • PRME’s TA Score: 4 bullish, 4 bearish.
  • SLDB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both PRME and SLDB are a good buy in the short-term.

Price Growth

PRME (@Biotechnology) experienced а -1.70% price change this week, while SLDB (@Biotechnology) price change was -11.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.65%, and the average quarterly price growth was -1.89%.

Reported Earning Dates

PRME is expected to report earnings on Mar 06, 2025.

SLDB is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($379M) has a higher market cap than SLDB($131M). PRME YTD gains are higher at: -1.027 vs. SLDB (-18.250). SLDB has higher annual earnings (EBITDA): -108.63M vs. PRME (-207.13M). PRME (176M) and SLDB (171M) have equal amount of cash in the bank . SLDB has less debt than PRME: SLDB (24.7M) vs PRME (41.2M). PRME has higher revenues than SLDB: PRME (800K) vs SLDB (0).
PRMESLDBPRME / SLDB
Capitalization379M131M289%
EBITDA-207.13M-108.63M191%
Gain YTD-1.027-18.2506%
P/E RatioN/AN/A-
Revenue800K0-
Total Cash176M171M103%
Total Debt41.2M24.7M167%
FUNDAMENTALS RATINGS
PRME vs SLDB: Fundamental Ratings
PRME
SLDB
OUTLOOK RATING
1..100
1467
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
19
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9096
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
6450

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (19) in the Biotechnology industry is somewhat better than the same rating for PRME (72) in the null industry. This means that SLDB’s stock grew somewhat faster than PRME’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that SLDB’s stock grew similarly to PRME’s over the last 12 months.

SLDB's SMR Rating (98) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that SLDB’s stock grew similarly to PRME’s over the last 12 months.

PRME's Price Growth Rating (90) in the null industry is in the same range as SLDB (96) in the Biotechnology industry. This means that PRME’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for PRME (100) in the null industry. This means that SLDB’s stock grew significantly faster than PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRMESLDB
RSI
ODDS (%)
Bullish Trend 5 days ago
90%
Bullish Trend 5 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 5 days ago
76%
Momentum
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
90%
MACD
ODDS (%)
Bullish Trend 5 days ago
75%
Bearish Trend 5 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 5 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
86%
Bearish Trend 5 days ago
90%
Advances
ODDS (%)
Bullish Trend 16 days ago
77%
Bullish Trend 24 days ago
80%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
76%
Aroon
ODDS (%)
Bearish Trend 5 days ago
81%
Bearish Trend 5 days ago
90%
View a ticker or compare two or three
Ad is loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+0.70%
CRSP - PRME
62%
Loosely correlated
+0.57%
BEAM - PRME
61%
Loosely correlated
+0.17%
NTLA - PRME
58%
Loosely correlated
+0.85%
RXRX - PRME
55%
Loosely correlated
+2.03%
ALLO - PRME
54%
Loosely correlated
-1.09%
More

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with TRDA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
+0.62%
TRDA - SLDB
42%
Loosely correlated
+1.20%
PLRX - SLDB
41%
Loosely correlated
-3.36%
MGTX - SLDB
40%
Loosely correlated
+5.56%
INZY - SLDB
40%
Loosely correlated
N/A
PRME - SLDB
40%
Loosely correlated
+0.70%
More